Creative Biolabs combines a full suite of end-to-end services to help partners move promising ideas from the lab bench to clinical application.
While chimeric antigen receptor T cell therapy has seen tremendous success in hematologic malignancies, efficacy in solid tumors has been hindered thus far by several factors, including antigenic heterogeneity and the inherently immunosuppressive TME.
“We truly believe that no single strategy can cope with the complexity of a solid tumor; therefore, our CAR-T therapy solutions are multi-pronged, integrating advanced cell engineering, precise antigen targeting, and strategic combinatorial approaches designed to enhance the efficacy, persistence, and safety of T-cell immunotherapies,” said a scientist from Creative Biolabs.
Creative Biolabs offers comprehensive, fully integrated CAR-T cell therapy development services for solid tumor indications. The integrated approach covers every stage from the initial target discovery and validation to preclinical testing and regulatory support.
* CellRapeutics one-stop TCR-T development for solid tumors
Services include neoantigen identification and TCR discovery, TCR affinity optimization, TCR gene engineering and cell manufacturing, functional characterization, and preclinical and clinical translation support.
Furthermore, TIL represents a revolutionary step forward in treating solid tumors, using the body’s immune system to target and destroy cancerous cells, the scientist said.
With more than 20 years of experience in the industry, Creative Biolabs has been instrumental in optimizing the therapeutic uses of TILs and driving their adoption as a feasible and effective treatment modality against cancer.
“Our strategic focus on refining TIL extraction, cultivation, and infusion processes has empowered us to address the challenges of immunotherapy resistance, particularly in ‘cold’ solid tumors that typically exhibit lower immunogenicity,” added the leading scientist.
TIL therapy has shown potential efficacy in various kinds of cancer, such as melanoma, cervical cancer, and even some of the refractory malignancies like non-small cell lung cancer and colorectal cancer.
Solutions at Creative Biolabs range from a combination of TIL therapy with immune checkpoint inhibitors to achieve synergistic effects that amplify anti-tumor responses and durable outcomes, thus broadening the application spectrum of TIL therapy,” added the leading scientist.
For more information, please visit our website.
About Creative Biolabs
Creative Biolabs is a leading Contract Research Organization (CRO) specializing in cell and gene therapy development. Its portfolio spans CAR-T, TCR-T, TIL therapy, and cancer vaccines, partnering with innovators across the globe to accelerate breakthroughs in immunotherapy.
Leads in the Innovation of Solid Tumor Adoptive Cell Therapy Development
